PE20171340A1 - Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales - Google Patents
Composicion farmaceutica para el tratamiento de enfermedades gastrointestinalesInfo
- Publication number
- PE20171340A1 PE20171340A1 PE2017001147A PE2017001147A PE20171340A1 PE 20171340 A1 PE20171340 A1 PE 20171340A1 PE 2017001147 A PE2017001147 A PE 2017001147A PE 2017001147 A PE2017001147 A PE 2017001147A PE 20171340 A1 PE20171340 A1 PE 20171340A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- gastrointestinal diseases
- pharmaceutical composition
- bismuth
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150015339 | 2015-01-30 | ||
KR1020150147513A KR101583452B1 (ko) | 2015-01-30 | 2015-10-22 | 위장질환 치료용 의약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171340A1 true PE20171340A1 (es) | 2017-09-13 |
Family
ID=55169799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001147A PE20171340A1 (es) | 2015-01-30 | 2016-01-28 | Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP3250199A4 (zh) |
JP (1) | JP6419347B2 (zh) |
KR (2) | KR101583452B1 (zh) |
CN (1) | CN107205947B (zh) |
AR (1) | AR105413A1 (zh) |
CL (1) | CL2017001680A1 (zh) |
CO (1) | CO2017006222A2 (zh) |
EA (1) | EA032385B9 (zh) |
EC (1) | ECSP17038599A (zh) |
GE (1) | GEP20196941B (zh) |
MA (1) | MA41432A (zh) |
MX (1) | MX2017007567A (zh) |
MY (1) | MY195824A (zh) |
PE (1) | PE20171340A1 (zh) |
PH (1) | PH12017550051A1 (zh) |
SA (1) | SA517382016B1 (zh) |
TW (1) | TWI635859B (zh) |
UA (1) | UA116517C2 (zh) |
WO (1) | WO2016122226A2 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101988479B1 (ko) | 2017-10-11 | 2019-09-24 | (주)휴럼 | 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물 |
WO2019199134A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 약제학적 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE81011T1 (de) * | 1987-03-09 | 1992-10-15 | Procter & Gamble | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. |
US4990610A (en) * | 1988-08-25 | 1991-02-05 | Applied Analytical Industries, Inc. | Method for preparing high potency sucralfate |
EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
KR970006083B1 (ko) * | 1992-01-22 | 1997-04-23 | 주식회사 대웅제약 | 위장질환 치료용 의약 조성물 |
ES2173183T3 (es) * | 1994-04-26 | 2002-10-16 | Chugai Pharmaceutical Co Ltd | Procedimiento de preparacion de sucralfato granulado y fundido. |
JPH0879097A (ja) * | 1994-09-01 | 1996-03-22 | Matsushita Electric Ind Co Ltd | 携帯無線機 |
KR970006083A (ko) | 1995-07-06 | 1997-02-19 | 한승준 | 자동차용 카울부의 와이어 고정장치 취부구조 |
AU8354498A (en) * | 1997-08-25 | 1999-03-16 | Procter & Gamble Company, The | Combined preparations for treating upper gastrointestinal tract distress |
CN1173698C (zh) | 1999-06-21 | 2004-11-03 | 株式会社大熊制药 | 包含包衣的雷尼替丁、碱式柠檬酸铋和硫糖铝的对胃肠障碍具有治疗作用的可口服给药的药物制剂 |
JP2006076956A (ja) * | 2004-09-10 | 2006-03-23 | Taiyo Yakuhin Kogyo Kk | 胃炎の治療・予防用配合剤 |
KR101617054B1 (ko) * | 2008-07-01 | 2016-04-29 | 라이온 가부시키가이샤 | 고형내복제제 |
KR20110105223A (ko) * | 2010-03-18 | 2011-09-26 | 일양약품주식회사 | 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물 |
KR20140072673A (ko) | 2012-12-05 | 2014-06-13 | (주)한국파비스제약 | 경구용 위장질환 치료를 위한 정제 |
-
2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active IP Right Review Request
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko active Application Filing
-
2016
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/en not_active Withdrawn
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/en active Application Filing
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 MX MX2017007567A patent/MX2017007567A/es active IP Right Grant
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es unknown
-
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
TWI635859B (zh) | 2018-09-21 |
ECSP17038599A (es) | 2017-09-29 |
KR20160094268A (ko) | 2016-08-09 |
EP3250199A2 (en) | 2017-12-06 |
MY195824A (en) | 2023-02-22 |
SA517382016B1 (ar) | 2021-03-18 |
AR105413A1 (es) | 2017-10-04 |
CN107205947B (zh) | 2020-05-22 |
KR101583452B1 (ko) | 2016-01-11 |
EP3250199A4 (en) | 2018-08-08 |
WO2016122226A2 (en) | 2016-08-04 |
JP2018503672A (ja) | 2018-02-08 |
MX2017007567A (es) | 2017-10-19 |
CN107205947A (zh) | 2017-09-26 |
TW201639559A (zh) | 2016-11-16 |
UA116517C2 (uk) | 2018-03-26 |
PH12017550051A1 (en) | 2018-01-29 |
EA032385B9 (ru) | 2019-07-31 |
CL2017001680A1 (es) | 2018-01-12 |
CO2017006222A2 (es) | 2017-09-20 |
EA201791458A1 (ru) | 2017-11-30 |
EA032385B1 (ru) | 2019-05-31 |
JP6419347B2 (ja) | 2018-11-07 |
KR101583452B9 (ko) | 2022-05-02 |
WO2016122226A3 (en) | 2016-09-15 |
GEP20196941B (en) | 2019-01-10 |
BR112017013857A2 (pt) | 2018-02-27 |
MA41432A (fr) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
BR112017016503A2 (zh) | Ligand - cytotoxic drug conjugates, their preparation and their use | |
CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
GT201700016A (es) | [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
BR112014032583A2 (pt) | forma farmacêutica para liberação prolongada de substâncias ativas | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
PE20171340A1 (es) | Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
CL2018002848A1 (es) | Formulaciones liquidas de fosfoplatino | |
CO2018010142A2 (es) | Proceso de preparación de fórmulas solidas de mesalazina | |
EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
CL2017003465A1 (es) | Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria. | |
CL2017000026A1 (es) | Formas de dosificación farmacéutica |